Log In
Print this Print this

omigapil (SNT-317, TCH-346)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionSelegiline derivative that targets glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Molecular Target Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationMuscular dystrophy
Indication DetailsTreat congenital muscular dystrophy
Regulatory Designation U.S. - Fast Track (Treat congenital muscular dystrophy);
U.S. - Orphan Drug (Treat congenital muscular dystrophy);
EU - Orphan Drug (Treat congenital muscular dystrophy)
PartnerSanthera Pharmaceuticals Holding AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today